2022 Speakers
Wednesday, April 27, 2022
Zoom Webinar Event
Creighton University, Omaha, Nebraska
9:00 AM CDT (16:00 CET) - 3:30 PM CDT (22:30 CET)
Zoom Webinar Event
Creighton University, Omaha, Nebraska
9:00 AM CDT (16:00 CET) - 3:30 PM CDT (22:30 CET)
The Symposium recording will be made available for 2 weeks to revisit your favorite presentations
Passcode: w4Tpp+8s
Speaker Information
Featured Speakers
Angela Ruohao Wu, PhD
Assistant Professor The Hong Kong University of Science and Technology "scONE-seq: A one-tube single-cell multi-omics method enables dissection of frozen glioblastoma heterogeneity" Angela Ruohao Wu is an assistant professor in the Division of Life Science and the Department of Chemical and Biological Engineering at The Hong Kong University of Science and Technology. She completed her Ph.D., and post-doctoral training in Bioengineering at Stanford University. Angela is one of the earliest in the world to work in single cell genomics (Nature Methods 2014; Nature 2014). She also pioneered the field of microfluidic chromatin immunoprecipitation (ChIP) and invented the first microfluidic chip for automated ChIP (Lab Chip 2009). Her current research uses genomics and microfluidics to address complex biological questions, developing innovative technological platforms for precise cellular analysis and manipulation, as well as translating genomics solutions into the clinic. Angela was named one of MIT Technology Review Innovators under 35 Asia in 2016; a World Economic Forum Young Scientist in 2018, and an Outstanding Young Faculty by IEEE EMBS (Micro and Nanotechnology in Medicine) in 2018. |
Ludovic Deriano, PhD
Dr./Research Director Institut Pasteur "Origin of somatic mutations in lymphoid cancer: Role of V(D)J recombinase" Dr. Deriano received his B.Sc in Biochemistry at the Open University in England, and completed his PhD at the Paris 5 René Descartes University in France. From there he went to Dr. David Roth’s lab as a post-doctoral fellow where he helped discover roles for the RAG proteins is directing pathway choice in the repair of DNA double strand breaks during V(D)J recombination, and in suppressing genome instability and lymphomagenesis. This is where I came to know his work and met him at meetings. After his post-doctoral training, he joined the Institut Pasteur in Paris in 2012 as a Chargé de recherche, equivalent to our Principle Investigator – Assistant Professor, and has worked his way up to Directeur de Researche. He is currently Head of Lymphocyte Development & Oncogenesis 5-year Junior Group in the Department of Immunology and Department of Genomes and Genetics. His main research interest is in elucidating mechanisms that determine DNA repair pathway choice, particularly in the context of programmed DNA double strand breaks in lymphocytes, and how genome stability and suppression of oncogenesis are maintained during this process. He has been very productive in this area, and has received significant funding and recognition for his work. |
John Pierce Wise, Sr., PhD
Professor of Pharmacy & Toxicology, Wise Laboratory of Environmental and Genetic Toxicology, Dept. of Pharmacology & Toxicology, University of Louisville "Mechanisms of Metal-Induced Chromosome Instability" Dr. John Pierce Wise, Sr. is head of the Wise Laboratory of Environmental and Genetic Toxicology, Professor of Pharmacology and Toxicology and a Distinguished University Scholar in the School of Medicine at the University of Louisville. He is a recipient of the prestigious Revolutionizing Innovative, Visionary Environmental Health Research (RIVER) R35 grant from the National Institute of Environmental Health Sciences (NIEHS). As head of his laboratory, Dr. Wise leads a team of faculty, staff and students who conduct state-of-the-art research aimed at understanding how environmental chemicals affect health and cause cancer. In particular, Dr. Wise leads a strong toxicology research program focused on cellular and molecular mechanisms in cancer biology and chemical carcinogenesis that includes human and wildlife studies utilizing a One Environmental Health Approach. Gregg B. Fields, PhD, FNAI
Executive Director Institute for Human Health & Disease Intervention (I-HEALTH) Florida Atlantic University "Application of Novel Matrix Metalloproteinase Inhibitors in Cancer" Gregg B. Fields is the Executive Director of the Institute for Human Health & Disease Intervention (I-HEALTH) and a Full Professor in the Department of Chemistry & Biochemistry at Florida Atlantic University, and an Adjunct Professor in the Department of Chemistry at The Scripps Research Institute/Scripps Florida. He received his B.S. and Ph.D. degrees in chemistry from the University of Florida and Florida State University, respectively, and was a Postdoctoral Scholar at the University of California at San Francisco. The Fields research group has focused on extracellular protease-based diseases, with particular attention paid to tumor metastasis, arthritis, and neurodegenerative diseases. |
Wenyi Wei, PhD
Professor Beth Israel Deaconess Medical Center "Targeting the Ubiquitin Pathway for Cancer Therapies" Dr. Wenyi Wei received his B.A. degree from Shandong University in 1993 and then obtained his M.S. training in Chinese Academy of Science from 1993 to 1996. Afterwards, Dr. Wei received his Ph.D. training in the MCB department at Brown University and his postdoctoral training in the laboratory of Dr. William Kaelin, Jr. at DFCI, Harvard Medical School. Dr. Wei became independent from 2006 in Department Pathology at Beth Israel Deaconess Medical Center, Harvard Medical School. The major focus of the WEI laboratory is aimed at understanding how aberrant cell signaling events contribute to cell cycle dysregulation and subsequent tumorigenesis, which will offer the molecular basis and the rationale to develop novel anti-cancer therapies targeting specific cell signaling pathways. Thomas W. Glover, PhD, FACMG
Professor, Human Genetics, Pediatrics and Pathology, Dept. of Human Genetics, University of Michigan Medical School “Mechanisms of Genomic Copy Number Alterations” Dr. Glover is Professor in the Departments of Human Genetics, Pediatrics and Pathology, University of Michigan. He received his PhD from Michigan State University and did Postdoctoral work at the University of Hawaii on some of the earliest studies of the fragile X syndrome. He is a Founding Fellow. American College of Medical Genetics and Fellow, American Association for the Advancement of Science (AAAS). His main research focus is on the mechanisms responsible for the formation of genomic copy number alterations/variants, which have profound effects on genome variation, evolution and disease and arise frequently in many cancers. |
Timothy Fleming, PhD
Professor/Senior Scientist, Norton Thoracic Institute, St. Joseph Hospital "Targeted Therapy for Esophageal Cancer" Dr. Fleming received his PhD in Microbiology/Immunology from the University of MO-Columbia in 1985. Dr. Fleming did a post-doctoral fellowship at the National Cancer Institute from 1985-1987. Dr. Fleming became a NCI Staff Scientist from 1987-1991, at the Lab of Cellular and Molecular Biology. Dr. Fleming was an Asst./Assoc./Full Professor at Washington University School of Medicine from 1991-2017. In 2017, Dr. Fleming became a Senior Scientist/Professor at the Norton Thoracic Institute at St. Joseph Hospital, Phoenix, AZ. |
Narendra Sankpal, PhD
Research Scientist, Norton Thoracic Institute, St. Joseph Hospital "Role of Membrane proteins in Tumor cell growth and metastasis" I joined Norton Thoracic Institute, St. Joseph's Hospital and Medical Center as a faculty member to study LKB1, Ras, EGFR and EpCAM genes in lung cancer and develop therapeutics. I’m also responsible for studies in organ transplant. I have extensive training and experience in the field of cancer biology, genetics, and immunotherapy from Washington University School of Medicine. I have a broad background in chemistry, biochemistry, molecular biology, Bioinformatics, genetics and therapeutic developments for clinical trials. For clinical trials, I have designed, produced DNA vaccines for personalized cancer therapy. I am a self-motivated, independent researcher driven to carry out proposed research projects with collaborative efforts. I intend to use, stem cell as a drug delivery vehicles, discovery of molecular markers in cancer, develop recombinant proteins and antibodies for cancer therapy. |